Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit.

@article{Dangelo2013SelectionAM,
  title={Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit.},
  author={Salvatore D'angelo and Mario Secondulfo and Raffaele De Cristofano and Paolo P Sorrentino},
  journal={Future oncology},
  year={2013},
  volume={9 4},
  pages={485-91}
}
Sorafenib (SO) was the first systemic agent to demonstrate a significant improvement in overall survival in patients with advanced hepatocellular carcinoma (HCC); international guidelines now recommend SO as a first-line treatment in patients with unresectable HCC who are not eligible for locoregional therapies and maintain preserved liver function. However, therapy with SO may require close management to further optimize the clinical outcomes and limit the onset of adverse events (AEs). SO has… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.
5 Citations
39 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 39 references

a retrospective analysis of efficacy, safety, and survival benefits

  • J Chiu, YF Tang, cirrhosis Yao TJ et al. The use of single-agent sorafenib in liver
  • Cancer 118(21), 5293–52301
  • 2012
1 Excerpt

an update

  • Rolle E De Giorgio M et al. Cabibbo G, 11 1807–1816.nPracticalrecommendationsonthemanagement, with a focus on the importance of a multidisciplinary a HCC
  • www.aasld.org/practiceguidelines/ Documents…
  • 2012
1 Excerpt

recommendations from the Sorafenib Working Group

  • S Bracarda, EM Ruggeri, Monti M et al. Early detection, prevention, management of cutaneous adverse events due to sorafenib
  • Crit. Rev. Oncol. Hematol. 82(3), 378–386
  • 2012

what can we learn from routine clinical practice? Expert Rev

  • R Sacco, I Bargellini, +11 authors Sorrentino www.futuremedicine.com 491 future science group he carcinoma
  • Anticancer Ther. 12(7), 869–875
  • 2012
1 Excerpt

Similar Papers

Loading similar papers…